DUBLIN, IRELAND--(Marketwire - Feb 4, 2013) - Elsevier Business Intelligence, publisher of "The Gray Sheet" and the medtech industry's leading provider of strategic partnership and investment conferences, will host the 'Investment-in-Innovation (IN3) Medical Device 360 Dublin' partnering and investment conference on April 16-18, 2013, at the The Shelbourne Dublin. This special event, which will bring together a diverse group of medtech's key thought leaders from among corporate business development execs, venture capital and angel investors, start-up entrepreneurs and industry pioneers, will feature a panel discussion:
"Strategics on Deal Priorities: Driving Growth through Different Structures." Virtually all medtech exits take place by M&A. What are the strategics looking for when acquiring? In this interactive session, large device company executives will share their insights about what they like to see from smaller venture-backed companies and how they are driving growth through M&A. Discussion points will include:
- What is the current appetite for deals? Compared to previous years?
- Thin pickings or window of opportunities? How suitable is the startup community in creating the environment to do more deals?
- Building the infrastructure to do more deals
- Focusing on revenue generating companies
- Tuck-in acquisitions vs. white space deals: where to focus
- Growth through non-traditional markets: which areas can supplement growth?
Confirmed speakers at IN3 Dublin are: David Cassak (moderator), Vice President, Content, Elsevier Business Intelligence; Steve Levin (moderator), Editor-in-Chief, Elsevier Business Intelligence; Chad Cornell, Vice President, Corporate Development, Medtronic; Townsend Goddard, Director, Business Development & Strategic Planning, Stryker Corporation; Dennis Crowley, VP, Corporate Development & Licensing, Covidien; Edward Andrle, VP, Business Development, Sorin Group; Zeev Zehavi, Vice President, Venture Investments, Johnson and Johnson Development Corporation, and Amir Blumenfeld, Head of Discovery for Edwards Lifesciences.
Investors confirmed to attend to date include senior-level dealmakers from Abingworth, Delta Partners, Earlybird Venture Capital, Fountain Healthcare Partners, Gilde, Imperial Innovations, NBGI Ventures, Omnes Capital, Peppermint Venture Partners, Seroba Kernel, Sofinnova, and Wellington Partners. Corporate investors confirmed to attend to date include Bard, Covidien, Edwards Lifesciences, Johnson & Johnson, Sorin, and Stryker.
In addition to all of the customary conference benefits, presenting company CEOs will have the opportunity to be interviewed on camera, at no charge, for a 3-minute exclusive video in which they may discuss their company and technology. These interviews will be featured post-conference at www.in3tv.com, to which a link will be provided to participating companies for their unrestricted use; availability of these video interviews will be broadly promulgated within the medtech industry. All one-on-one interviews with presenting-company CEOs will take place at, and during the IN3 Dublin conference and be organized by medtech PR/IR expert Ronald Trahan, President of Ronald Trahan Associates, Inc. Videotaping will take place on a scheduled basis only, on one day only of the event: Wednesday, April 17, from 13:00-17:30 local time. To schedule the free on-camera interviews contact firstname.lastname@example.org, or call +1-508-359-4005, x108.
IN3 Medical Device 360 Dublin will be held at The Shelbourne Dublin. Event co-sponsors include Ronald Trahan Associates Inc., Aptiv Solutions, Enterprise Ireland, Eugene F. Collins, KPMG, Seroba Kernel, and Marketwire. Visit www.in3dublin.com for full conference and registration details.
This two-day special event will benefit a wide variety of participants in the medical device sector: start-ups seeking investment or strategic partnerships, investment firms, VCs, mid-size and large medical device manufacturers, and service providers. Emerging medtech companies that would like to apply to present in Dublin should contact Kayleen Kell at 949-797-7142, or email email@example.com
About Elsevier Business Intelligence
Elsevier Business Intelligence (EBI), an Elsevier company built on the heritage of F-D-C Reports, Windhover Information and Medtech Insight, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, EBI places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. EBI (www.elsevierbi.com) has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.
- Investment & Company Information
- business development
Ronald Trahan, APR
Ronald Trahan Associates Inc.